drugset / Trial / NCT02103283
A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.
Timeline
- Start
- 2014-10
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teprotumumab | Monoclonal antibody | 20 mg/kg | Intravenous |